Glitazones: the evidence from PROactive, DREAM and ADOPT
Authors
Abstract
Professor Barnett describes the results of three major longterm studies of glitazones in the treatment of type 2 diabetes and the advantages these new agents may have over established treatments. Copyright © 2007 Wiley Interface Ltd
Digital Object Identifier (DOI)
10.1002/psb.85 About DOI
Login/Logout
Journal Menu
- Home
- News
- Current Issue
- Archive Issues
- Learning Central
- Ask Prescriber
- Prescriber Blog
- Forthcoming Events
- Supplements
- Wiley Job Network
Advertising and Sponsorship
Other Journals
